肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

AACR 2020：伯瑞替尼治疗MET异常NSCLC，ORR达30.5%

2020-04-29 找药宝典 找药宝典

AACR 2020伯瑞替尼
关注

伯瑞替尼治疗c-Met 异常的晚期非小细胞肺癌的I期临床试验结果公布这是一个开放性、多中心的I期临床研究，共纳入37例经治但未接受过c-Met抑制剂或HGF靶向治疗的局部晚期或转移性晚期NSCLC患者

伯瑞替尼治疗c-Met 异常的晚期非小细胞肺癌的I期临床试验结果公布这是一个开放性、多中心的I期临床研究，共纳入37例经治但未接受过c-Met抑制剂或HGF靶向治疗的局部晚期或转移性晚期NSCLC患者(NCT02896231)。研究分为剂量递增（19例）和剂量扩展（18例）两个阶段进行。

研究结果显示，8例患者仅检出c-MET过表达，11例仅携带Ex14跳读，8例仅检出MET基因扩增，另外10例患者检出不止一种MET变异。伯瑞替尼总体耐受性良好，未出现剂量限制性毒性。在所有可评估疗效的患者中（N=36），伯瑞替尼的ORR为30.5%(11/36) ，疾病控制率（DCR）为94.4% (34/36)。

亚组分析显示，c-MET过表达、扩增或Ex14跳跃突变的患者中，ORR 分别为30.6%, 41.2% 和 66.7%；在携带c-MET过表达且伴随基因扩增的患者(N=6)中的ORR为50%；在携带MET基因Ex14跳读且伴随基因扩增的患者(N=4)中，ORR达100%。

伯瑞替尼是中国第一个从大数据模拟、靶点验证到高通量筛选的精准治疗药物，该药物的临床试验获得了国家“十三五”重大新药创制专项资助。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853123, encodeId=cc7f1853123ce, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Sep 25 05:58:03 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896646, encodeId=226d189664684, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Jan 22 13:58:03 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400468, encodeId=fc071400468d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552006, encodeId=05ef1552006af, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590700, encodeId=53881590e0023, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622850, encodeId=21481622850ce, content=<a href='/topic/show?id=777c26081cc' target=_blank style='color:#2F92EE;'>#伯瑞替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26081, encryptionId=777c26081cc, topicName=伯瑞替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039765, encodeId=a48c1039e65a3, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 13:58:03 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-09-25 tamgche

    #AACR 2020#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1853123, encodeId=cc7f1853123ce, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Sep 25 05:58:03 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896646, encodeId=226d189664684, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Jan 22 13:58:03 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400468, encodeId=fc071400468d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552006, encodeId=05ef1552006af, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590700, encodeId=53881590e0023, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622850, encodeId=21481622850ce, content=<a href='/topic/show?id=777c26081cc' target=_blank style='color:#2F92EE;'>#伯瑞替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26081, encryptionId=777c26081cc, topicName=伯瑞替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039765, encodeId=a48c1039e65a3, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 13:58:03 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2021-01-22 一闲

    #MET#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1853123, encodeId=cc7f1853123ce, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Sep 25 05:58:03 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896646, encodeId=226d189664684, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Jan 22 13:58:03 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400468, encodeId=fc071400468d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552006, encodeId=05ef1552006af, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590700, encodeId=53881590e0023, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622850, encodeId=21481622850ce, content=<a href='/topic/show?id=777c26081cc' target=_blank style='color:#2F92EE;'>#伯瑞替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26081, encryptionId=777c26081cc, topicName=伯瑞替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039765, encodeId=a48c1039e65a3, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 13:58:03 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-05-01 10518094zz

    #ACR#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1853123, encodeId=cc7f1853123ce, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Sep 25 05:58:03 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896646, encodeId=226d189664684, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Jan 22 13:58:03 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400468, encodeId=fc071400468d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552006, encodeId=05ef1552006af, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590700, encodeId=53881590e0023, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622850, encodeId=21481622850ce, content=<a href='/topic/show?id=777c26081cc' target=_blank style='color:#2F92EE;'>#伯瑞替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26081, encryptionId=777c26081cc, topicName=伯瑞替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039765, encodeId=a48c1039e65a3, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 13:58:03 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-05-01 Luyuxie_14

    #AACR#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1853123, encodeId=cc7f1853123ce, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Sep 25 05:58:03 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896646, encodeId=226d189664684, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Jan 22 13:58:03 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400468, encodeId=fc071400468d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552006, encodeId=05ef1552006af, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590700, encodeId=53881590e0023, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622850, encodeId=21481622850ce, content=<a href='/topic/show?id=777c26081cc' target=_blank style='color:#2F92EE;'>#伯瑞替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26081, encryptionId=777c26081cc, topicName=伯瑞替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039765, encodeId=a48c1039e65a3, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 13:58:03 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-05-01 psybestwish

    #ORR#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1853123, encodeId=cc7f1853123ce, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Sep 25 05:58:03 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896646, encodeId=226d189664684, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Jan 22 13:58:03 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400468, encodeId=fc071400468d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552006, encodeId=05ef1552006af, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590700, encodeId=53881590e0023, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622850, encodeId=21481622850ce, content=<a href='/topic/show?id=777c26081cc' target=_blank style='color:#2F92EE;'>#伯瑞替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26081, encryptionId=777c26081cc, topicName=伯瑞替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039765, encodeId=a48c1039e65a3, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 13:58:03 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-05-01 爆笑小医

    #伯瑞替尼#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1853123, encodeId=cc7f1853123ce, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Sep 25 05:58:03 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896646, encodeId=226d189664684, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Jan 22 13:58:03 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400468, encodeId=fc071400468d0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552006, encodeId=05ef1552006af, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590700, encodeId=53881590e0023, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622850, encodeId=21481622850ce, content=<a href='/topic/show?id=777c26081cc' target=_blank style='color:#2F92EE;'>#伯瑞替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26081, encryptionId=777c26081cc, topicName=伯瑞替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri May 01 01:58:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039765, encodeId=a48c1039e65a3, content=NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 13:58:03 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-04-29 肿肿

    NSCLC下一步突破在于新靶点了，靶向治疗和免疫治疗基本见顶了，再有新的就需要新机制了

    0

相关资讯

AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析

PACIFIC是第一项证明能够改善无法切除的III期非小细胞肺癌（NSCLC）生存的研究，将改写III期NSCLC的治疗标准。III期无法切除NSCLC的5年生存率为15%~30%左右，在长达几十年中

AACR 2020：Capmatinib治疗MET 14突变的NSCLC脑转移疗效

NSCLC是一种常见的肺癌类型，每年影响人数超过200万人，据估计，有3％~4％的NSCLC患者具有MET突变。Capmatinib是目前全球唯一上市的选择性MET抑制剂。

AACR 2020：波奇替尼治疗NSCLC的EGFR 20ins的II期研究

EGFR突变是非小细胞肺癌中最常见的靶点，不过同样是EGFR突变，为何部分患者靶向治疗的效果更差或者很快耐药。其中一项重要的原因就是EGFR上还存在一些罕见突变，比如20ins、G719x、L861Q

AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）

Keynote 042是PD1单抗K药获批用于PDL1阳性（≥1%）晚期NSCLC一线治疗的基于研究。既往研究中，患者若出现STK11和KEAP1突变，则提示对免疫药物疗效差。此次分析了研究中S

AACR 2020：拉罗替尼治疗TRK融合肿瘤的亚组分析

拉罗替尼是FDA获批用于NTRK融合晚期实体瘤患者的首个靶向药

AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究)

RELAY研究评价厄洛替尼联合雷莫芦单抗（人源化VEGFR-2 IgG1抗体）对比厄洛替尼+安慰剂一线治疗EGFR突变阳性晚期NSCLC的疗效及安全性。

拓展阅读

AACR重磅：局部晚期或转移性胃/GEJ癌患者使用抗TTX-030联合化学免疫疗法的一线治疗的安全性有效性评估

TTX-030、布加利单抗和FOLFOX的组合作为1L治疗LA/M胃/GEJ癌，无论CPS状态如何，都表现出良好的疗效

AACR重磅之SPOTLIGHT203试验：瘤内注射BO-112联合帕博丽珠单抗对PD-1免疫治疗耐药的晚期黑色素瘤患者的疗效

BO-112是一种由聚乙烯亚胺配制的双链合成RNA，模拟病毒感染。

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

在有MET扩增的EGFR突变型NSCLC患者中，特泊替尼+吉非替尼大大改善了PFS和OS。

AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果

一线帕博丽珠单抗继续延长了中国晚期/转移性PD-L1阳性NSCLC患者的OS，并在随访近4年后提供了持久的反应。

AACR重磅：高基因扩增和肿瘤突变负荷组合作为接受替雷丽珠单抗治疗患者的泛癌生物标志物

TMB和HA的组合对用替雷利珠单抗治疗各种实体瘤类型的临床获益有预测作用。

AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究

tTMB和bTMB都没有与PFS获益显著相关，表明在TIS+化疗作为晚期nsq-NSCLC一线治疗的情况下，tTMB和bTMB的临床效用有限。